Merck's first-quarter results showed a significant decline in revenue and lowered 2009 guidance due to challenges like loss of product exclusivity and vaccine supply issues. While there are positive signs from cost-cutting measures and progress in the merger with Schering-Plough, the overall sentiment is cautious, pointing to short-term headwinds for the stock.

[-1]